Cancer Research

KFRC is dedicated to generate impactful scientific insights that directly contribute to the early detection and prognosis of cancer. Our goal is to move beyond traditional diagnostic and therapeutic frameworks by integrating molecular technologies and precision medicine into clinical practice.

A central area of focus is the development of liquid biopsy approaches, which offer a non-invasive, real-time snapshot of tumor dynamics. These methods have immense potential for monitoring disease progression, predicting therapeutic response, and detecting cancer at early stages. In particular, we are exploring the role of circulating tumor DNA (ctDNA) in breast cancer, where quantifying and analyzing ctDNA fragments can help identify minimal residual disease and potential relapse well before conventional imaging techniques.

In parallel, the department is investigating exosomal microRNAs (miRNAs) in glioma, a highly aggressive form of brain cancer. These small, non-coding RNA molecules, encapsulated in extracellular vesicles like exosomes, serve as stable and accessible biomarkers that reflect the molecular state of the tumor. By profiling specific miRNAs, we aim to develop novel diagnostic and prognostic tools that are both sensitive and specific to glioma subtypes.

Another critical initiative involves the use of next-generation sequencing (NGS) to study myelodysplastic syndromes (MDS)—a group of disorders characterized by ineffective blood cell production and a high risk of progression to leukemia. Through targeted NGS panels, we aim to identify mutations associated with drug resistance and disease progression, paving the way for more personalized treatment strategies.

Our research also delves into the tumor microenvironment, particularly the role of tumor-associated macrophages (TAMs) in modulating cancer growth, metastasis, and immune evasion. Understanding how TAMs interact with cancer cells and influence therapeutic outcomes could unlock new avenues for immunotherapy and combination treatment approaches.

Our department is working to translate laboratory findings into clinically actionable solutions, by integrating molecular diagnostics, advanced sequencing technologies, and tumor biology.